| What matters in ADVANCE and ADVANCE-ON. | |
| | |
MedLine Citation:
|
PMID: 22118707 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Most recent meta-analyses of morbidity-mortality risk hazards brought about by the presence of diabetes as compared with non-diabetics underline the dominant risk of renal disease and cardiovascular outcomes and the relevance of blood glucose, blood pressure (BP) and cholesterol levels. The translation of this reality into therapeutic guidelines always requires interventional evidence. Evidence for combined approaches in controlling for BP and blood glucose was provided by Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation (ADVANCE), conducted in over 11 000 subjects from 20 countries. Reduction in systolic BP by 7.1 mm Hg, in diastolic BP by 2.9 mm Hg and in glycated haemoglobin A1c by 0.61% points in the combined routine BP lowering and intensive blood glucose-control group after an average 4.3 years of follow-up resulted in a relative risk reduction of 28% in renal events, 24% in cardiovascular death and 18% in all-cause mortality. While other major intervention trials performed in similar populations with analogous goals did not achieve the same level of positive therapeutic evidence and even pointed to some risk of intensified treatment of type 2 diabetes, all three major studies [Action to Control Cardiovascular Risk in Diabetes (ACCORD), Veterans Affairs Diabetes Trial (VADT) and ADVANCE] showed significant reduction in renal events, the major risk in type 2 diabetes. The divergence for other outcomes underlines the importance of considering specific therapeutic approaches for glucose control and prudent targets for BP. The current target values for glycated haemoglobin of 6.5-7% and for BP of 130/80 mmHg appear safe and beneficial. The potential long-term benefit, particularly that of initial tight blood glucose control, suggested by recent post-trial evidence is currently being evaluated in the ADVANCE-ON study. |
| | |
Authors:
|
P Hamet |
Related Documents
:
|
16384847 - Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. 21747287 - Effect of culturally tailored diabetes education in ethnic minorities with type 2 diabe... 458037 - Experimental infusion thrombophlebitis. a comparison between glucose and frutcose and 5... 9827847 - Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insuli... 15638867 - Ghrelin and adiponectin in patients with cushing's disease before and after successful ... 16984237 - The long-term effects of rosiglitazone on serum lipid concentrations and body weight. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 14 Suppl 1 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 20-9 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
CRCHUM-Technopôle Angus, 2901 rue Rachel Est, Montréal (Québec) H1W 4A4, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treating diabetes today with gliclazide MR: a matter of numbers.
Next Document: Gender differences in the disability (functional limitations) associated with cardiovascular disease...